Baxter International Inc vs Invesco S&P 500 Momentum ETF — how do they compare? Baxter International Inc trades at $22.16 (market cap $11.26B), while Invesco S&P 500 Momentum ETF trades at $149.44. The key difference: Baxter International Inc pays a 0.92% dividend while Invesco S&P 500 Momentum ETF pays none, and Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, Baxter International Inc nearer its low. Which is the better fit depends on your goals.
| BAX | SPMO | |
|---|---|---|
Market Cap | $11.26B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $29.22 | $161.66 |
52-Week Low | $15.80 | $107.84 |
Enterprise Value | $18.93B | — |
Dividend Yield | 0.92% | — |
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
SPMO trades at $149.73, down 2.61% today, with a neutral technical signal. The ETF maintains a bullish moving average trend but faces resistance near $150. Recent news highlights strong momentum performance, gaining 7.5% in June 2026, driven by concentrated technology exposure and AI beneficiaries. A dividend of $0.25 is scheduled for June 2026.
Outlook remains positive with AI-driven growth potential, but risks include high volatility from sector concentration. Analyst sentiment is mixed, with some recommending buys for momentum exposure. Key support is at $149, with upside resistance at $151-$153.
Trailing returns across standard periods
Latest headlines on both assets
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →